The MEK inhibitor trametinib plus the RTK inhibitor anlotinib induces synergistic antitumor efficacy in KRAS-mutant NSCLC, potentially via the MEK/RTK-IGFBP2-RTK signaling loop. Here, KRAS is linked to non-small cell lung carcinoma.